Four University Of Montreal Discoveries To Be Commercialized By Univalor And Cognitive Sensing Inc.

Cutting-edge technologies are about to enter the marketplace, thanks to a new partnership between Gestion Univalor, Limited Partnership (Univalor) and Cognitive Sensing Inc. (CSI), a privately owned technology company based in Montreal.

Univalor, which commercializes discoveries from the Université de Montréal and its affiliated institutions, and CSI have announced the signature of a license agreement giving CSI exclusive worldwide rights to develop, manufacture and market four scientifically proven products developed by Jocelyn Faubert, a professor at the Université de Montréal School of Optometry and CSI’s chief science officer.

Among the most anticipated products to emanate from Professor Faubert’s lab is a portable sports simulator that allows athletes to improve their game and reaction time. Another technology opens doors to the early detection, measurement and treatment of concussions and conditions such as Alzheimer’s and autism.

“We are impressed by the quality of the research generated by Prof. Jocelyn Faubert and his team. Technologies created in his lab present exciting market opportunities in the medical, sports and rejuvenation markets,” says Jean Castonguay, chief executive officer of CSI and a seasoned entrepreneur. “CSI has already entered into agreements with Industry leaders to validate the first applications of these technologies”.

Adds Marc Leroux, CEO of Univalor: “We are delighted to associate these Université de Montréal technologies with CSI and their experienced management team. We look forward to a lasting relationship.”

Patented technologies: Scientific validation of Prof. Faubert’s technologies was established in numerous peer-reviewed journals such as Brain and Psychological Science. His creations are currently being tested at several centers; the first are set for commercial validation in January 2010. Under the licensing agreement, CSI will provide financial support for patent protection in various territories in addition to other payments. The patented technologies include:

* MPI (Mild Perceptual Impairment Device): An apparatus to diagnose and monitor brain trauma, concussions, Alzheimer’s disease and other neurobiological conditions.

* 3D-MOT (3D Multiple Object Tracking): A device to enhance sports performance, as well as assess, train and improve perception in people of all ages.

* MSRS (Multisensory Stochastic Resonance Stimulation): A technology to improve sense and balance via auditory and visual stimulation.

* Noisy Bits: Software to improve image quality in standard displays and projectors by generating continuous luminance.

Source: Sylvain-Jacques Desjardins
University of Montreal

Go to Source

People who read this also read

• Eradicating MRSA With New Plasma Technology
  MRSA (methicillin-resistant Staphylococcus Aureus) and other drug-resistant bacteria could face annihilation as low-temperature plasma prototype devices have been developed to offer safe, quick, easy and unfailing bactericidal cocktails. Two prototype devices have been developed: one for efficien...
• Posttraumatic Stress Disorder Professionals Laud DMS’s Friedman, Schnurr
  The International Society of Traumatic Stress Studies (ISTSS) recently honored Dartmouth Medical School (DMS) faculty members Matthew J. Friedman, M.D., Ph.D., and Paula P. Schnurr, Ph.D., for their work as co-founders of the National Center for Posttraumatic Stress Disorder (PTSD). Friedman, a p...
• Of Pfizer, a New Treatment for a Rare Disease and Carrot Cells
  Pfizer’s deal today with Israeli biotech Protalix BioTherapeutics to license most of the rights for a promising therapy for a rare disease caught our eye for a number of reasons: The deal gives Pfizer rights to sell a treatment for Gaucher’s disease that will soon go for FDA approval. Pf...
• New Breast MRI Technology Enables Enhanced Breast Cancer Detection
  The launch of Invivo Corporation's ONCAD for DynaCAD marks the availability of the first FDA-cleared, fully-automated morphological system for the detection and analysis by a radiologist of suspicious breast lesions. The ONCAD system will be officially unveiled at the Radiological Society of North A...
• Knockouts In Human Cells Point To Pathogenic Targets
  Whitehead researchers have developed a new type of genetic screen for human cells to pinpoint specific genes and proteins used by pathogens, according to their paper in Science. In most human cell cultures genes are present in two copies: one inherited from the father and one from the mother. Gen...